Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 6
1995 9
1996 11
1997 10
1998 7
1999 8
2000 10
2001 9
2002 9
2003 7
2004 2
2005 6
2006 11
2007 12
2008 17
2009 15
2010 22
2011 24
2012 24
2013 37
2014 36
2015 39
2016 37
2017 51
2018 49
2019 53
2020 67
2021 58
2022 44
2023 58
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

690 results

Results by year

Filters applied: . Clear all
Page 1
Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis.
Hsu PL, Chien CW, Tang YA, Lin BW, Lin SC, Lin YS, Chen SY, Sun HS, Tsai SJ. Hsu PL, et al. Sci Adv. 2023 Apr 14;9(15):eade3422. doi: 10.1126/sciadv.ade3422. Epub 2023 Apr 12. Sci Adv. 2023. PMID: 37043564 Free PMC article.
The metastasis-promoting function of nuclear TYRO3 requires its kinase activity and matrix metalloproteinase-2 (MMP-2)-mediated cleavage but is independent of ligand binding. Using proteomic analysis, we identified bromodomain-containing protein 3 (BRD3), an acetyl-lysine …
The metastasis-promoting function of nuclear TYRO3 requires its kinase activity and matrix metalloproteinase-2 (MMP-2)-mediated cleav …
TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.
Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, Chang SS, Yamaguchi H, Lee HH, Ke B, Hsu JM, Chan LC, Hortobagyi GN, Yang L, Lin C, Yu D, Hung MC. Jiang Z, et al. J Clin Invest. 2021 Apr 15;131(8):e139434. doi: 10.1172/JCI139434. J Clin Invest. 2021. PMID: 33855973 Free PMC article.
Inhibition of TYRO3 promoted tumor ferroptosis and sensitized resistant tumors to anti-PD-1 therapy. Collectively, our findings suggest that TYRO3 could serve as a predictive biomarker for patient selection and a promising therapeutic target to overcome anti-PD-1/PD …
Inhibition of TYRO3 promoted tumor ferroptosis and sensitized resistant tumors to anti-PD-1 therapy. Collectively, our findings sugge …
Regulation of bone homeostasis by MERTK and TYRO3.
Engelmann J, Zarrer J, Gensch V, Riecken K, Berenbrok N, Luu TV, Beitzen-Heineke A, Vargas-Delgado ME, Pantel K, Bokemeyer C, Bhamidipati S, Darwish IS, Masuda E, Burstyn-Cohen T, Alberto EJ, Ghosh S, Rothlin C, Hesse E, Taipaleenmäki H, Ben-Batalla I, Loges S. Engelmann J, et al. Nat Commun. 2022 Dec 12;13(1):7689. doi: 10.1038/s41467-022-33938-x. Nat Commun. 2022. PMID: 36509738 Free PMC article.
The fine equilibrium of bone homeostasis is maintained by bone-forming osteoblasts and bone-resorbing osteoclasts. Here, we show that TAM receptors MERTK and TYRO3 exert reciprocal effects in osteoblast biology: Osteoblast-targeted deletion of MERTK promotes increased bone …
The fine equilibrium of bone homeostasis is maintained by bone-forming osteoblasts and bone-resorbing osteoclasts. Here, we show that TAM re …
Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
Myers KV, Amend SR, Pienta KJ. Myers KV, et al. Mol Cancer. 2019 May 14;18(1):94. doi: 10.1186/s12943-019-1022-2. Mol Cancer. 2019. PMID: 31088471 Free PMC article. Review.
These macrophages serve as a promising target for treatment of cancer due to their roles in promoting cancer progression and simultaneous immunosuppression. The TAM receptors (Tyro3, Axl and MerTK) are promising therapeutic targets on tumor-associated macrophages. ...
These macrophages serve as a promising target for treatment of cancer due to their roles in promoting cancer progression and simultaneous im …
TYRO3: A potential therapeutic target in cancer.
Hsu PL, Jou J, Tsai SJ. Hsu PL, et al. Exp Biol Med (Maywood). 2019 Feb;244(2):83-99. doi: 10.1177/1535370219828195. Epub 2019 Feb 2. Exp Biol Med (Maywood). 2019. PMID: 30714403 Free PMC article. Review.
In this review, we summarize the molecular biology of a unique member of a subfamily of receptor tyrosine kinase, TYRO3 and discuss the new insights in TYRO3-targeted treatment for cancer therapy....
In this review, we summarize the molecular biology of a unique member of a subfamily of receptor tyrosine kinase, TYRO3 and discuss t …
TYRO3 protects podocyte via JNK/c-jun-P53 pathway.
Zhang L, Jiang S, Shi J, Xu X, Wang L, Zhai X, Hou Q, Qin W, Chen Z. Zhang L, et al. Arch Biochem Biophys. 2023 May 1;739:109578. doi: 10.1016/j.abb.2023.109578. Epub 2023 Mar 21. Arch Biochem Biophys. 2023. PMID: 36948351
TYRO3 expression was suppressed by high glucose and TGF-beta, which may contribute to the decreased TYRO3 expression in progressive DKD. ...Our results revealed a novel signaling module of TYRO3 in podocyte homeostasis, which provides a new molecular insight …
TYRO3 expression was suppressed by high glucose and TGF-beta, which may contribute to the decreased TYRO3 expression in progre …
TYRO3 agonist as therapy for glomerular disease.
Zhong F, Cai H, Fu J, Sun Z, Li Z, Bauman D, Wang L, Das B, Lee K, He JC. Zhong F, et al. JCI Insight. 2023 Jan 10;8(1):e165207. doi: 10.1172/jci.insight.165207. JCI Insight. 2023. PMID: 36454644 Free PMC article.
Among the 3 TAM receptors (TYRO3, AXL, and MER), only TYRO3 expression is largely restricted to podocytes, and glomerular TYRO3 mRNA expression negatively correlates with human glomerular disease progression. ...Among the small-molecule TYRO3 agonistic …
Among the 3 TAM receptors (TYRO3, AXL, and MER), only TYRO3 expression is largely restricted to podocytes, and glomerular T …
Tyro3, Axl, Mertk receptor-mediated efferocytosis and immune regulation in the tumor environment.
Zhou L, Matsushima GK. Zhou L, et al. Int Rev Cell Mol Biol. 2021;361:165-210. doi: 10.1016/bs.ircmb.2021.02.002. Epub 2021 May 10. Int Rev Cell Mol Biol. 2021. PMID: 34074493 Review.
Three structurally related tyrosine receptor cell surface kinases, Tyro3, Axl, and Mertk (TAM) have been recognized to modulate immune function, tissue homeostasis, cardiovasculature, and cancer. ...
Three structurally related tyrosine receptor cell surface kinases, Tyro3, Axl, and Mertk (TAM) have been recognized to modulate immun …
The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.
Smart SK, Vasileiadi E, Wang X, DeRyckere D, Graham DK. Smart SK, et al. Cancers (Basel). 2018 Nov 29;10(12):474. doi: 10.3390/cancers10120474. Cancers (Basel). 2018. PMID: 30501104 Free PMC article. Review.
While AXL and MERTK have been extensively studied, less is known about TYRO3. Recent studies revealed roles for TYRO3 in cancer and suggest TYRO3 as a therapeutic target in this context. ...Translational agents that target TYRO3 are also described....
While AXL and MERTK have been extensively studied, less is known about TYRO3. Recent studies revealed roles for TYRO3 in cance …
TYRO3 Knockdown Suppresses the Growth of Myeloid Leukaemia Cells.
Saito T, Itoh M, Tohda S. Saito T, et al. Anticancer Res. 2022 Apr;42(4):1757-1761. doi: 10.21873/anticanres.15652. Anticancer Res. 2022. PMID: 35346994
BACKGROUND/AIM: TYRO3 is a member of the TAM family (TYRO3, AXL, and MERTK) of receptor tyrosine kinases. ...TYRO3 knockdown potently suppressed TYRO3 mRNA expression but not that of AXL and MERTK. ...
BACKGROUND/AIM: TYRO3 is a member of the TAM family (TYRO3, AXL, and MERTK) of receptor tyrosine kinases. ...TYRO3 knoc …
690 results